Key clinical point: The combination of brentuximab vedotin and rituximab is an effective chemotherapy-sparing strategy to achieve early remission in patients with immunosuppression-associated CD30-positive and/or EBV-positive lymphoid malignancies.

Major finding: Overall survival at 12 months was 90%, with a progression-free survival at 12 months of 75%.

Study details: A phase 1/ 2 trial in patients with post-transplant lymphoproliferative disorder. Among the 20 patients in the trial, the most common histology was monomorphic diffuse large B-cell lymphoma.

Disclosures: Dr. Pearse reported having no financial disclosures. Co-investigators on the study reported relationships with Seattle Genetics, Celgene, AbbVie, and other companies.